89bio Inc Stock Investor Sentiment

ETNB Stock  USD 8.99  0.15  1.64%   
About 56% of 89bio's investor base is looking to short. The analysis of the overall investor sentiment regarding 89bio Inc suggests that many traders are alarmed. The current market sentiment, together with 89bio's historical and current headlines, can help investors time the market. In addition, many technical investors use 89bio Inc stock news signals to limit their universe of possible portfolio assets.
  

89bio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards 89bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at benzinga.com         
89bio To Rally 265 Here Are 10 Other Analyst Forecasts For Thursday
benzinga news
over a year ago at investing.com         
89bio Inc. Announces Proposed 200M Share Offering
Investing News at Macroaxis
over a year ago at globenewswire.com         
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Macroaxis News: globenewswire.com
over a year ago at bizjournals.com         
Why S.F. biotechs clinical trial may add to new dash for fatty liver disease NASH
bizjournals News
over a year ago at thelincolnianonline.com         
Cantor Fitzgerald Raises 89bio Price Target to 45.00
news
over a year ago at investorplace.com         
LAZR Stock Price Predictions Why This Analyst Says Luminar Is Worth Just 5
sbwire news
over a year ago at marketwatch.com         
89bios stock rallies 48 percent on new NASH data
marketwatch News
over a year ago at reuters.com         
89Bios NASH drug meets main goals of mid-stage study
reuters
over a year ago at investing.com         
89bio Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved High Statistical Significance on Both ...
Investing News at Macroaxis
over a year ago at finance.yahoo.com         
89bios Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis Achieved High Statisti...
Yahoo News
over a year ago at marketwatch.com         
89bios stock rallies 48 percent on new NASH data
marketwatch News
over a year ago at thelincolnianonline.com         
Royal Bank of Canada Reaffirms Outperform Rating for 89bio
news
over a year ago at zacks.com         
Wall Street Analysts See an 80 percent Upside in 89BIO Can the Stock Really Move This High?
zacks News
over a year ago at zacks.com         
Mirums Livmarli Gets FDA Nod for Expanded Use, Stock Up
zacks News
over a year ago at investing.com         
89bio earnings beat by 0.21, revenue was in line with estimates
Investing News at Macroaxis
Far too much social signal, news, headlines, and media speculation about 89bio that are available to investors today. That information is available publicly through 89bio media outlets and privately through word of mouth or via 89bio internal channels. However, regardless of the origin, that massive amount of 89bio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of 89bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 89bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 89bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 89bio alpha.

89bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 16527 shares by Rohan Palekar of 89bio at 18.95 subject to Rule 16b-3
09/06/2024
2
Disposition of 5352 shares by Le-nguyen Quoc of 89bio at 8.46 subject to Rule 16b-3
09/09/2024
3
Disposition of 9671 shares by Mansbach Harry H of 89bio at 11.53 subject to Rule 16b-3
09/27/2024
4
Acquisition by Le-nguyen Quoc of 8334 shares of 89bio subject to Rule 16b-3
10/14/2024
5
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis at AASLD The Liver Meeting 2024
10/15/2024
6
Short Interest in 89bio, Inc. Declines By 7.1
10/18/2024
7
Disposition of 27955 shares by Le-nguyen Quoc of 89bio at 8.12 subject to Rule 16b-3
10/30/2024
8
Acquisition by Atkinson Edward Morrow Iii of 45150 shares of 89bio at 9.98 subject to Rule 16b-3
11/07/2024
9
89bio Launches 100M Public Offering to Advance Pegozafermin Development ETNB ETNB Stock News - StockTitan
11/12/2024
10
89bio drops 2, prices 125M stock offering
11/13/2024
11
Janus Henderson Group PLCs Strategic Acquisition in 89bio Inc
11/14/2024
12
RA CAPITAL MANAGEMENT, L.P. Increases Stake in 89bio Inc - GuruFocus.com
11/19/2024
13
Acquisition by Rohan Palekar of 10000 shares of 89bio at 8.35 subject to Rule 16b-3
11/22/2024
14
Acquisition by Le-nguyen Quoc of 195000 shares of 89bio at 9.98 subject to Rule 16b-3
11/25/2024
15
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635
11/29/2024

Complementary Tools for 89bio Stock analysis

When running 89bio's price analysis, check to measure 89bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 89bio is operating at the current time. Most of 89bio's value examination focuses on studying past and present price action to predict the probability of 89bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 89bio's price. Additionally, you may evaluate how the addition of 89bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments